Melanoma March has officially launched
5 February 2015
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.
The launch event held at Tonic House in Melbourne’s CBD revealed plans for the new funding. There will be 23 marches that are happening around Australia, with the first march kicking off in Melbourne on the 22nd February.
Professor Graham Mann, Research Director at MIA, explained how the Melanoma March campaign provides critical funding for our expert clinicians to get one step closer to finding a cure. He revealed the beneficiary of the 2015 initiative will be the next phase of the Melanoma Genome Project.
“Monies raised from last year’s Melanoma March campaign contributed to the world-first PD-1 Brain Metastases Trial - that is currently underway,” he said.
“Half of all patients diagnosed with stage 4 melanoma will develop brain metastases at some point during their illness. Until now, treatment has been unavailable and as such the clinicians at Melanoma Institute Australia are committed to developing new treatment options that provide potential hope to patients with brain metastases and could prove to be a significant step in finding a cure.
“Funds raised from the 2015 Melanoma March campaign will enable Melanoma Institute Australia and melanoma research centres around the nation to work together to launch a study which hopes to enable melanoma cells to be isolated, banked, distributed and tested against new treatments. This approach is a powerful way to capitalise on new knowledge from gene and immunity analysis that is showing where melanoma is vulnerable to attack.
Known as ‘Australia’s national cancer’, Australia has the highest incidence of melanoma in the world with over 12,500 new cases diagnosed each year, equating to one person dying every six hours from melanoma in Australia. Sadly, melanoma kills more young Australians (15-39 year-olds) than any other single cancer, proving why continual funding for research is key in addressing this devastating illness.
The Melbourne launch was also attended by former AFL icon and melanoma survivor, Tim McGrath as well as award winning musician Bob Corbett and channel Ten news presenter Brad McEwen.
To see where your local march is and how you can get involved to help us raise $1 million for melanoma research click here.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.